Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES

    Vaccines for Children

    Sol. 75D30125D00195JustificationATLANTA, GA
    Closed
    STATUS
    Closed
    POSTED
    Aug 21, 2025
    Publication date
    NAICS CODE
    325412
    Primary industry classification
    PSC CODE
    6505
    Product & service classification

    AI Summary

    The CDC is awarding multiple IDIQ contracts for the purchase of pediatric and adult vaccines, including Clesrovimab for RSV prevention. This opportunity supports immunization programs under the Public Health Service Act. Interested parties may submit proposals for consideration.

    Contract details

    Solicitation No.
    75D30125D00195
    Notice Type
    Justification
    Posted Date
    August 21, 2025
    Response Deadline
    NAICS Code
    325412AI guide
    PSC / Class Code
    6505
    Contract Code
    7523
    Primary Contact
    James Sprigler
    State
    GA
    ZIP Code
    30333
    AI Product/Service
    product

    Award information

    Award Date
    April 1, 2025

    Description

    CDC Office of Acquisition Services awarded multiple indefinite delivery, indefinite quantity (IDIQ) contracts for the National Center for Immunization and Respiratory Diseases (NCIRD) for the purchase of standard commercial pediatric & adult vaccines, manufactured under a current establishment and product license issued by the U.S. Food and Drug Administration (FDA). The vaccines awarded under these contracts will be purchased for NCIRD’s immunization awardees (the fifty state health departments, several large city program and current and former U.S. Territories) to support immunization programs as provided under Section 317(j) of the Public Health Service Act and VFC, as established pursuant to Section 13631 of the Omnibus Budget Reconciliation Act of 1993. The initial pediatric contracts, awarded in April 2025 were established to support public sector ACIP recommended routine vaccinations for children. Merck’s pediatric contract will be modified to support purchase of Clesrovimab (Enflonsia), which is indicated for the prevention of RSV lower respiratory tract disease, hospitalization, and death in neonates and infants who are born during or entering their first RSV season, in light of the ACIP approval and accompanying VFC resolution on June 25, 2025. Clesrovimab from Merck is the second product currently licensed for the prevention of RSV in neonates and infants to prevent severe RSV disease. CDC’s current pediatric contract with Merck will be modified to include ~750,000 doses required to support purchase of Clesrovimab to administer to VFC eligible neonates and newborns. CDC intends on awarding a sole source follow on action to Merck to allow for the addition of Clesrovimab. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.

    Key dates

    1. August 21, 2025Posted Date
    2. April 1, 2025Award Date

    AI search tags

    Frequently asked questions

    Vaccines for Children is a federal contract award from DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the award details including the awardee, contract value, and NAICS code.

    SamSearch Platform

    Stop searching. Start winning.

    AI-powered intelligence for the right opportunities, the right leads, and the right time.